Prevención y manejo de la hipertrofia ventricular izquierda en pacientes adultos obesos.
DOI:
https://doi.org/10.56048/MQR20225.7.2.2023.342-357Palabras clave:
Hipertrofia ventricular izquierda, terapéutica, obesidad, prevención y control.Resumen
En Ecuador los riesgos cardiovasculares es la primera causa de muerte, entre ellas tenemos la Hipertrofia Ventricular Izquierda y los factores de riesgos es la hipertensión arterial, pero estudios actuales han caracterizado que la obesidad independientemente puede también desencadenar esta patología afectando más a mujeres que a hombres y así se promueve una prevención primaria y un diagnóstico precoz.
Se evidenció que el sobrepeso y la obesidad en la infancia se asocian con daños cardiovasculares, sin embargo, esto aumentó significativamente la morbimortalidad en la edad adulta llegando a padecer una HVI avanzada.
Los antihipertensivos detienen el progreso y mejora la hipertrofia ventricular izquierda, asi como, la pérdida de peso o la restricción de sodio en la dieta tienen efectos beneficiosos adicionales sobre el sistema cardiovascular. También se ha demostrado un beneficio significativo en el manejo terapéutico como los diuréticos tiazídicos, los inhibidores del sistema renina-angiotensina-aldosterona (RAAS) y los bloqueadores de los canales de calcio (CCB) hasta los inhibidores del cotransportador de sodio-glucosa tipo 2 (SGLT2).
Descargas
Métricas
Cited
DOI: 10.56048
Citas
Trachsel LD, Ryffel CP, de Marchi S, Seiler C, Brugger N, Eser P, et al. Exercise-induced cardiac remodeling in non-elite endurance athletes: Comparison of 2-tiered and 4-tiered classification of left ventricular hypertrophy. 2018 [cited 2022 Dec 17]; Available from: https://doi.org/10.1371/journal.pone.0193203
Valarezo-Sevilla D, Pazmiño-Martínez A, Morales-Mora N, Básico Jipijapa Jipijapa H, San Francisco Sangolquí C. Prevalencia de hipertrofia ventricular izquierda en pacientes diabéticos. Rev Peru Med Exp Salud Publica. 2013;30(1):69–72.
AlRahimi J, Aboud A, AlQuhaibi AS, Almaghrabi Y, Alghamdi YS, Mufti HN. Effect of Isolated Obesity on Left Ventricular Function and Structure: A Single-Center Experience. Cureus [Internet]. 2021 Mar 19 [cited 2022 Nov 18];13(3). Available from: https://pubmed.ncbi.nlm.nih.gov/33880308/
Lovic D, Narayan P, Pittaras A, Faselis C, Doumas M, Kokkinos P. Left ventricular hypertrophy in athletes and hypertensive patients. J Clin Hypertens (Greenwich) [Internet]. 2017 Apr 1 [cited 2022 Dec 15];19(4):413–7. Available from: https://pubmed.ncbi.nlm.nih.gov/28247560/
Trandafir LM, Russu G, Moscalu M, Miron I, Lupu VV, Leon Constantin MM, et al. Waist circumference a clinical criterion for prediction of cardio-vascular complications in children and adolescences with overweight and obesity. Medicine [Internet]. 2020 Jul 24 [cited 2022 Nov 27];99(30):e20923. Available from: https://journals.lww.com/md- journal/Fulltext/2020/07240/Waist_circumference_a_clinical_criterion_for.19.aspx
Brady TM. The Role of Obesity in the Development of Left Ventricular Hypertrophy Among Children and Adolescents. Curr Hypertens Rep [Internet]. 2016 Jan 1 [cited 2022 Dec 15];18(1):1–7. Available from: https://pubmed.ncbi.nlm.nih.gov/26700209/
Pedersen LR, Kristensen AMD, Petersen SS, Vaduganathan M, Bhatt DL, Juel J, et al. Prognostic implications of left ventricular hypertrophy diagnosed on electrocardiogram vs echocardiography. J Clin Hypertens (Greenwich) [Internet]. 2020 Sep 1 [cited 2022 Dec 15];22(9):1647–58. Available from: https://pubmed.ncbi.nlm.nih.gov/32813895/
Sayin BY, Oto A. Left Ventricular Hypertrophy: Etiology-Based Therapeutic Options. Cardiol Ther [Internet]. 2022 Jun 1 [cited 2022 Dec 17];11(2):203–30. Available from: https://pubmed.ncbi.nlm.nih.gov/35353354/
Johnson K, Oparil S, Davis BR, Tereshchenko LG. Prevention of Heart Failure in Hypertension-Disentangling the Role of Evolving Left Ventricular Hypertrophy and Blood Pressure Lowering: The ALLHAT Study. J Am Heart Assoc [Internet]. 2019 Apr 16 [cited 2022 Dec 15];8(8). Available from: https://pubmed.ncbi.nlm.nih.gov/30943832/
Dries DL. Natriuretic peptides and the genomics of left-ventricular hypertrophy. Heart Fail Clin [Internet]. 2010 Jan [cited 2022 Dec 15];6(1):55–64. Available from: https://pubmed.ncbi.nlm.nih.gov/19945061/
Cuspidi C, Facchetti R, Quarti-Trevano F, Dell’Oro R, Tadic M, Grassi G, et al. Left ventricular hypertrophy in isolated and dual masked hypertension. J Clin Hypertens (Greenwich) [Internet]. 2020 Apr 1 [cited 2022 Dec 15];22(4):673–7. Available from: https://pubmed.ncbi.nlm.nih.gov/31955495/
Schneider RH, Myers HF, Marwaha K, Rainforth MA, Salerno JW, Nidich SI, et al. Stress Reduction in the Prevention of Left Ventricular Hypertrophy: A Randomized Controlled Trial of Transcendental Meditation and Health Education in Hypertensive African Americans. Ethn Dis [Internet]. 2019 [cited 2022 Dec 15];29(4):577–86. Available from: https://pubmed.ncbi.nlm.nih.gov/31641325/
Tam MC, Lee R, Cascino TM, Konerman MC, Hummel SL. Current Perspectives on Systemic Hypertension in Heart Failure with Preserved Ejection Fraction. Curr Hypertens Rep [Internet]. 2017 Feb 1 [cited 2022 Dec 15];19(2). Available from: https://pubmed.ncbi.nlm.nih.gov/28233237/
Rubiś PP. Left ventricular hypertrophy: what lies beneath? Pol Arch Intern Med [Internet]. 2019 [cited 2022 Nov 18];129(12):945–8. Available from: https://pubmed.ncbi.nlm.nih.gov/31868864/
Manrique FGO, Acta Médica Colombiana vol. 39. Prevalencia de hipertrofia ventricular izquierda en pacientes hipertensos [Internet]. Red de Revistas Científicas de América Latina. 2014 [cited 2022 Nov 18]. p. 1–7. Available from: https://www.redalyc.org/pdf/1631/163132480007.pdf
Mendizábal B, Khoury P, Woo JG, Urbina EM. Racial Differences in the Influence of Risk Factors in Childhood on Left Ventricular Mass in Young Adulthood. J Pediatr [Internet]. 2020 Feb 1 [cited 2022 Nov 18];217:152–7. Available from: https://pubmed.ncbi.nlm.nih.gov/31810626/
Li X, Guo X, Chang Y, Zhang N, Sun Y. Analysis of alterations of serum inflammatory cytokines and fibrosis makers in patients with essential hypertension and left ventricular hypertrophy and the risk factors. Am J Transl Res [Internet]. 2022 [cited 2023 Feb 4];14(6):4097. Available from: /pmc/articles/PMC9274558/
Huynh QL, Venn AJ, Magnussen CG, Yang H, Dwyer T, Marwick TH. Risk factors for left ventricular dysfunction in adulthood: role of low birth weight. ESC Heart Fail [Internet]. 2021 Dec 1 [cited 2023 Feb 4];8(6):5403. Available from: /pmc/articles/PMC8712853/
Khamsai S, Sanlung T, Limpawattana P, Chindaprasirt J, Boonsawat W, Silaruks S, et al. Risk factors of left ventricular hypertrophy in obstructive sleep apnea. Biomed Rep [Internet]. 2023 Jan 1 [cited 2023 Feb 4];18(1). Available from: /pmc/articles/PMC9755921/
Moidu S, Oomen AT, Pillai G, VS S. Microalbuminuria as an Independent Risk Factor for Developing Concentric Left Ventricular Hypertrophy in Primary Hypertension: A Single-Center Observational Study From South India. Cureus [Internet]. 2022 Jan 11 [cited 2023 Feb 4];14(1). Available from: /pmc/articles/PMC8830508/
Maugeri A, Hruskova J, Jakubik J, Barchitta M, Re O lo, Kunzova S, et al. Independent Effects of Hypertension and Obesity on Left Ventricular Mass and Geometry: Evidence from the Cardiovision 2030 Study. J Clin Med [Internet]. 2019 Mar 1 [cited 2022 Dec 17];8(3). Available from: https://pubmed.ncbi.nlm.nih.gov/30884768/
Lewis AJM, Rayner JJ, Abdesselam I, Neubauer S, Rider OJ. Obesity in the absence of comorbidities is not related to clinically meaningful left ventricular hypertrophy. International Journal of Cardiovascular Imaging [Internet]. 2021 Jul 1 [cited 2022 Nov 27];37(7):2277–81. Available from: https://link.springer.com/article/10.1007/s10554-021-02207-1
Sun T, Xie J, Zhu L, Han Z, Xie Y. Left Ventricular Hypertrophy and Asymptomatic Cardiac Function Impairment in Chinese Patients with Simple Obesity using Echocardiography. Obes Facts [Internet]. 2015 Jul 22 [cited 2022 Dec 15];8(3):210–9. Available from: https://pubmed.ncbi.nlm.nih.gov/26087902/
Nam D, Reineke EL. Timing and Targeting of Treatment in Left Ventricular Hypertrophy. Methodist Debakey Cardiovasc J [Internet]. 2017 Jan 1 [cited 2022 Nov 28];13(1):9. Available from: /pmc/articles/PMC5385802/
Cai A, Liu L, Zhou D, Zhou Y, Tang S, Feng Y. The patterns of left ventricular alteration by adipose tissue distribution: implication for heart failure prevention. ESC Heart Fail [Internet]. 2021 Aug 1 [cited 2022 Nov 27];8(4):3093–105. Available from: https://onlinelibrary.wiley.com/doi/full/10.1002/ehf2.13415
Litwin SE, Adams TD, Davidson LE, McKinlay R, Simper SC, Ranson L, et al. Longitudinal Changes in Cardiac Structure and Function in Severe Obesity: 11-Year Follow-Up in the Utah Obesity Study. J Am Heart Assoc [Internet]. 2020 Jun 16 [cited 2022 Nov 27];9(12). Available from: https://pubmed.ncbi.nlm.nih.gov/32476544/
Coisne A, Ninni S, Ortmans S, Davin L, Kasprzak K, Longère B, et al. Epicardial fat amount is associated with the magnitude of left ventricular remodeling in aortic stenosis. Int J Cardiovasc Imaging [Internet]. 2019 Feb 15 [cited 2022 Dec 15];35(2):267–73. Available from: https://pubmed.ncbi.nlm.nih.gov/30334229/
Lewis AJM, Rayner JJ, Abdesselam I, Neubauer S, Rider OJ. Obesity in the absence of comorbidities is not related to clinically meaningful left ventricular hypertrophy. Int J Cardiovasc Imaging [Internet]. 2021 Jul 1 [cited 2022 Nov 18];37(7):2277–81. Available from: https://pubmed.ncbi.nlm.nih.gov/33730330/
Peters MN, Seliger SL, Christenson RH, Hong-Zohlman SN, Daniels LB, Lima JAC, et al. “Malignant” Left Ventricular Hypertrophy Identifies Subjects at High Risk for Progression to Asymptomatic Left Ventricular Dysfunction, Heart Failure, and Death: MESA (Multi-Ethnic Study of Atherosclerosis). [cited 2022 Dec 17]; Available from: http://jaha.ahajournals.org/content/7/4/e006619/DC1/embed/inline-supplementary-material-1.pdf
Yan M, Sun S, Xu K, Huang X, Dou L, Pang J, et al. Cardiac Aging: From Basic Research to Therapeutics. Oxid Med Cell Longev [Internet]. 2021 [cited 2022 Dec 15];2021. Available from: https://pubmed.ncbi.nlm.nih.gov/33777324/
Chan CT, Greene T, Chertow GM, Kliger AS, Stokes JB, Beck GJ, et al. Effects of frequent hemodialysis on ventricular volumes and left ventricular remodeling. Clin J Am Soc Nephrol [Internet]. 2013 Dec 6 [cited 2022 Dec 15];8(12):2106–16. Available from: https://pubmed.ncbi.nlm.nih.gov/23970131/
Maayah ZH, Levasseur J, Piragasam RS, Abdelhamid G, Dyck JRB, Fahlman RP, et al. 2-Methoxyestradiol protects against pressure overload-induced left ventricular hypertrophy OPEN. [cited 2022 Dec 17]; Available from: www.nature.com/scientificreports
Kjeldsen SE, Strand A, Julius S, Okin PM. Mechanism of angiotensin II type 1 receptor blocker action in the regression of left ventricular hypertrophy. J Clin Hypertens (Greenwich) [Internet]. 2006 [cited 2022 Dec 15];8(7):487–92. Available from: https://pubmed.ncbi.nlm.nih.gov/16849902/
McCarty MF. Nutraceutical, Dietary, and Lifestyle Options for Prevention and Treatment of Ventricular Hypertrophy and Heart Failure. Int J Mol Sci [Internet]. 2021 Apr 1 [cited 2022 Nov 18];22(7). Available from: https://pubmed.ncbi.nlm.nih.gov/33805039/
Publicado
Cómo citar
Número
Sección
Licencia
Derechos de autor 2023 MQRInvestigar
Esta obra está bajo una licencia internacional Creative Commons Atribución 4.0.
®
Los autores se comprometen a respetar la información académica de otros autores, y a ceder los derechos de autor a la Revista MQRInvestigar, para que el artículo pueda ser editado, publicado y distribuido. El contenido de los artículos científicos y de las publicaciones que aparecen en la revista es responsabilidad exclusiva de sus autores. La distribución de los artículos publicados se realiza bajo una licencia 
